BioPharma Drug Discovery

Eccogene and AstraZeneca Partner on ECC5004 for Cardiometabolic Diseases

Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical,...

 November 10, 2023 | News

Tempus Collaborates with Bristol Myers Squibb on Multimodal AI Research

"We are looking forward to expanding our relationship with Bristol Myers Squibb and furthering our shared commitment to advancing cancer research and treat...

 November 09, 2023 | News

AdvanCell Doses First Patient in 212Pb-ADVC001 Clinical Trial for Metastatic Prostate Cancer in Australia

“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...

 November 09, 2023 | News

KN026 was Granted Breakthrough Therapy Designation by CDE

Gastric cancer is one of the most common gastrointestinal malignancies in the world, and the number of new cases and deaths of gastric cancer in China...

 November 08, 2023 | News

Menarini Group and SciClone Pharma Partner to Bring ORSERDU® to China for Advanced Breast Cancer

ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations,...

 November 08, 2023 | News

CStone Partners with 3SBio for Nofazinlimab in China

CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in ma...

 November 02, 2023 | News

First Patient Enrolled in Phase III Trial of Boan Biotech's Nivolumab

Nivolumab is a monoclonal antibody that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 (PD-1) receptor...

 October 31, 2023 | News

Everest Medicines Receives Approval in Macau for Nefecon® in Primary IgA Nephropathy

 Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercializ...

 October 30, 2023 | News

Henlius Expands Partnership with Intas to Introduce Serplulimab in Europe and India

Intas to develop and commercialise serplulimab in Europe and India; Henlius to receive €42 million upfront payment, double-digit royalt...

 October 30, 2023 | News

Chime Biologics and Hope Medicine Accelerate First-in-Class Antibody Drug HMI-115 for Endometriosis and Androgenic Alopecia

  Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine...

 October 27, 2023 | News

FDA Approves PENBRAYA™: First Vaccine for 5 Common Meningococcal Serogroups in Teens

PENBRAYA™ provides the broadest serogroup coverage (meningococcal groups A, B, C, W and Y) of any meningococcal vaccine available in the U.S. ...

 October 23, 2023 | News

FDA Approves Pfizer's VELSIPITY™ for Severe UC in Adults

Pfizer Inc.  announced  that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selectiv...

 October 16, 2023 | News

MediLink and BioNTech Partner for Advanced Anti-Cancer Drug

Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of ...

 October 13, 2023 | News

Simplifying Drug Discovery: How Molecule AI's Empowers Researchers - An Interview with Molecule AI's Saurabh Singal

In an illuminating interview with BioPharma APAC, Saurabh Singal, the CEO-Founder of Molecule AI, delves into the transformative power of Molecule AI's pla...

 October 12, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close